Clinical trials: Advanced and/or Metastatic Solid Tumours
Locally Advanced Solid Tumors, Metastatic Solid Tumors
A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors
RX108 is a novel, potent, small-molecule inhibitor of Na+/K+-ATPase. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of RX108 in patients with locally advanced or metastatic…
- Trial name
- NCT03646071
- Testing
- RX108
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- NeuPharma, Inc.
Locally Advanced Solid Tumor, Metastatic Tumor
A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors
The goal of this clinical trial is to test the safety of TST003 in patients with cancer. The main question[s] it aims to answer are: What is the recommended dose patients can safely receive? How long does this drug remain in the…
- Conditions
- Locally Advanced Solid Tumor, Metastatic Tumor, Colorectal Adenocarcinoma
- Trial name
- NCT05731271
- Testing
- TST003
- Where
- 3 sites in United States
- Volunteers
- 111 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Advanced Solid Tumors
A Study of ZW191 in Participants With Solid Tumors
The purpose of this study is to find out if ZW191 is safe and can treat participants with advanced cancers, including ovarian, endometrial, and non-small cell lung cancers.
- Trial name
- NCT06555744
- Testing
- ZW191
- Where
- 27 sites in United States, Australia and 4 more
- Volunteers
- 145 people
- Sponsor
- Zymeworks BC Inc.
Advanced Solid Tumor
Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors
This study will evaluate the safety, pharmacokinetics, and anti-tumor efficacy of MHB036C in participants with advanced or metastatic solid tumors.
- Trial name
- NCT05642949
- Testing
- MHB036C
- Where
- 3 sites in Australia
- Volunteers
- 400 people
- Sponsor
- Minghui Pharmaceutical Pty Ltd
Advanced Solid Tumors
A Study of KC1036 in Patients with Advanced Solid Tumors
The purpose of this study is to evaluate the safety，tolerability, pharmacokinetics, and preliminary efficacy of KC1036 in participants with advanced recurrent or metastatic solid tumors.
- Trial name
- NCT04387916
- Testing
- KC1036
- Where
- 3 sites in China
- Volunteers
- 207 people
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
Solid Tumour
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers
This study is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of humanized anti-EGFR monoclonal antibody, HLX07, in patients with epithelial cancer who have failed standard therapy and deemed…
- Trial name
- NCT02648490
- Testing
- HLX07, Acetaminophen, dexamethasone
- Where
- 2 sites in United States, Taiwan
- Volunteers
- 19 people
- Sponsor
- Henlix, Inc
Advanced Solid Tumor, Metastatic Solid Tumor
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in…
- Trial name
- NCT06108050
- Testing
- JZP898, Pembrolizumab
- Where
- 10 sites in United States
- Volunteers
- 177 people
- Sponsor
- Jazz Pharmaceuticals
Neoplasms
A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors
This Phase Ib, open-label, dose-escalation study will evaluate the safety, tolerability, and pharmacokinetics of the combination of MOXR0916 and atezolizumab in participants with locally advanced, recurrent, or metastatic…
- Trial name
- NCT02410512
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody, MOXR0916, a humanized agonist anti-OX40 monoclonal antibody
- Where
- 27 sites in United States, Australia and 5 more
- Volunteers
- 610 people
- Sponsor
- Genentech, Inc.
BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC
Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors
This is a phase 1, multicenter, open-label, single-arm study to investigate the safety and tolerability of encorafenib 300 mg once daily (QD) monotherapy in adult Chinese participants with B-RAF Proto-oncogene, Serine/threonine…
- Conditions
- BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC, Melanoma
- Trial name
- OCEANI (NCT05003622)
- Testing
- Encorafenib
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Pierre Fabre Medicament
Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 482 patients.
- Trial name
- NCT05208047
- Testing
- CGT9486, Sunitinib, Midazolam
- Where
- 126 sites in United States, Argentina and 20 more
- Volunteers
- 482 people
- Sponsor
- Cogent Biosciences, Inc.
HER2-Positive Solid Tumor
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.
- Trial name
- NCT05523947
- Testing
- YH32367
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 147 people
- Sponsor
- Yuhan Corporation
Solid Tumor Malignancies, Colorectal Carcinoma
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383.
- Conditions
- Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC)
- Trial name
- NCT07030257
- Testing
- CP-383
- Where
- 13 sites in United States
- Volunteers
- 150 people
- Sponsor
- Tasca Therapeutics
Solid Tumor, Adult
Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours
The main purpose of this study is to evaluate the safety and tolerability of EVT801 in subjects with advanced or metastatic solid tumours.
- Trial name
- NCT05114668
- Testing
- EVT801
- Where
- 2 sites in France
- Volunteers
- 32 people
- Sponsor
- Kazia Therapeutics Limited
Solid Cancers
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
This Phase Ib, multicenter, single-arm, open-label study is designed to evaluate the effect of trastuzumab on QTcF interval and to characterize the effects of trastuzumab on carboplatin pharmacokinetics in patients with…
- Trial name
- NCT00927589
- Testing
- carboplatin, docetaxel, trastuzumab
- Where
- 20 sites in United States
- Volunteers
- 59 people
- Sponsor
- Genentech, Inc.
Neoplasms, Carcinoma, Non-Small-Cell Lung
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)
This study will determine the safety and tolerability and establish a preliminary recommended Phase 2 dose of V941(mRNA-5671/V941) as a monotherapy and in combination with pembrolizumab infusion.
- Conditions
- Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms
- Trial name
- NCT03948763
- Testing
- V941, Pembrolizumab
- Where
- 26 sites in United States, Australia and 5 more
- Volunteers
- 70 people
- Sponsor
- Merck Sharp & Dohme LLC
Hematologic Malignancies
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy
In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in patients with relapsed/refractory hematologic malignancies will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated…
- Trial name
- NCT05104775
- Testing
- GNC-035
- Where
- 7 sites in China
- Volunteers
- 33 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Part 1- Advanced Solid Tumors, Part 2- Advanced or Metastatic Gastric Cancer
Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ
This is an open label phase 1/1b study of Rilotumumab in Japanese subjects with advanced solid tumors or metastatic gastric esphagogastric (GEJ) adenocarcinoma.
- Conditions
- Part 1- Advanced Solid Tumors, Part 2- Advanced or Metastatic Gastric Cancer, Part 2- Advanced or Metastatic GEJ
- Trial name
- NCT01791374
- Testing
- Rilotumumab
- Where
- 7 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Amgen
Esophageal Cancer, Gastric Cancer
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in…
- Conditions
- Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT06500052
- Testing
- BL-M17D1
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Urothelial Carcinoma, Renal Cell Carcinoma
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types…
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT03170960
- Testing
- cabozantinib, atezolizumab
- Where
- 124 sites in United States, Australia and 7 more
- Volunteers
- 914 people
- Sponsor
- Exelixis
Solid Tumor Malignancies
A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
This study employs a non-randomized, open-label design to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of DC50292A tablets in patients with MTAP-deficient advanced or metastatic solid…
- Trial name
- NCT07071090
- Testing
- DC50292A
- Where
- 8 sites in China
- Volunteers
- 32 people
- Sponsor
- Heronova Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.